SPOP mutated/ CHD1 deleted lethal prostate cancer and abiraterone sensitivity.

CONCLUSION: SPOP mutated mCRPCs are strongly enriched for CHD1 loss. These tumors appear highly sensitive to abiraterone treatment.
PMID: 30068710 [PubMed - as supplied by publisher]

Source: Clinical Prostate Cancer - August 1, 2018 Category: Cancer & Oncology Authors: Boysen G, Nava Rodrigues D, Rescigno P, Seed G, Dolling DI, Riisnaes R, Crespo M, Zafeiriou Z, Sumanasuriya S, Bianchini D, Hunt J, Moloney D, Perez-Lopez R, Tunariu N, Miranda S, Figueiredo I, Ferreira A, Christova R, Gil V, Aziz S, Bertan C, de Oliveira Tags: Clin Cancer Res Source Type: research